ERBB2 and dermatomyositis: Predicted activation of ERBB2 only in DM is of interest given that DM, and not JDM, is associated with an increased risk of malignancy [2, 59], and ERBB2 over-expression is also associated with malignancies in numerous cancer types [60], although this needs further investigation in DM.